Condition: Tardive Dyskinesia · Sponsor: Neurocrine Biosciences
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
This description comes directly from the study's public registry record.
Neurocrine Medical Information Call Center · 1-877-641-3461 · medinfo@neurocrine.com
Always discuss trial participation with your own doctor first.
| Neurocrine Clinical Site | Bryant, Arkansas, United States | Recruiting |
| Neurocrine Clinical Site | Chino, California, United States | Recruiting |
| Neurocrine Clinical Site | Fountain Valley, California, United States | Recruiting |
| Neurocrine Clinical Site | Huntington Beach, California, United States | Recruiting |
| Neurocrine Clinical Site | Long Beach, California, United States | Recruiting |
| Neurocrine Clinical Site | Temecula, California, United States | Recruiting |
| Neurocrine Clinical Site | Torrance, California, United States | Recruiting |
| Neurocrine Clinical Site | Boca Raton, Florida, United States | Recruiting |
| Neurocrine Clinical Site | Bonita Springs, Florida, United States | Recruiting |
| Neurocrine Clinical Site | Hialeah, Florida, United States | Recruiting |
| Neurocrine Clinical Site | Miami, Florida, United States | Recruiting |
| Neurocrine Clinical Site | Orange City, Florida, United States | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07365462